Drug Trials Snapshot: NEXVIAZYME

NEXVIAZYME is an enzyme used for the treatment of patients 1 year of age and older with late-onset Pompe disease…

FDA Drug Safety Communication: UPDATE on Tumor Necrosis Factor (TNF) blockers and risk for pediatric malignancy

[11-03-2011] The U.S. Food and Drug Administration (FDA) is updating the public about its ongoing safety review of Tumor Necrosis…

Spotlight on CDER Science

FDA scientists carry out laboratory, clinical and analytical research to address knowledge gaps in drug development, healthcare technologies and post-market…

CDER Communications Testing: Optimizing Drug Information Through Target Audience Feedback

Social and behavioral scientists in CDER’s Office of Communications (OCOMM) collect feedback from target audience members on a variety of…

FDA Drug Safety Communication: FDA review results in new warnings about using general anesthetics and sedation drugs in young children and pregnant women

Repeated or lengthy use of general anesthetic and sedation drugs in children younger than 3 years or in pregnant women…

FDA Drug Safety Communication: FDA review finds no significant increase in risk of serious asthma outcomes with long-acting beta agonists (LABAs) used in combination with inhaled corticosteroids (ICS)

A U.S. Food and Drug Administration (FDA) review of four large clinical safety trials shows that treating asthma with long-acting…

Bioiberica, SAU – 629115 – 01/15/2025

CGMP/Active Pharmaceutical Ingredient (API)/Adulterated

Bioiberica, SAU – 629115 – 06/30/2022

CGMP/Active Pharmaceutical Ingredient (API)/Adulterated

Administration Studies in Equine Antidoping Research: Designing Scientific Investigations to Effectively Direct Medication Control in Racehorses

ABSTRACT Pharmacokinetics is the study of the movement of drug in the body and includes the processes of absorption, distribution,…

Registered Outsourcing Facilities

Discover FDA’s comprehensive list of registered outsourcing facilities engaged in human drug compounding. Get the latest updates, compliance guidelines, and…